Department of Internal Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1340-5. doi: 10.1016/j.ijrobp.2012.09.032. Epub 2012 Nov 22.
We sought to evaluate the prognostic/predictive value of ERCC1 and XPF in patients with nonmetastatic nasopharyngeal carcinoma (NPC) treated with curative intent.
ERCC1 and XPF protein expression was evaluated by immunofluorescence combined with automated quantitative analysis (AQUA) using the FL297 and 3F2 antibodies, respectively. ERCC1 and XPF protein expression levels were correlated with clinical outcomes.
Patient characteristics were as follows: mean age 52 years (range, 18-85 years), 67% male, 72% Karnofsky performance status (KPS) ≥ 90%, World Health Organization (WHO) type 1/2/3 = 12%/28%/60%, stage III/IV 65%. With a median follow-up time of 50 months (range, 2.9 to 120 months), the 5-year overall survival (OS) was 70.8%. Median standardized nuclear AQUA scores were used as cutpoints for ERCC1 (n=138) and XPF (n=130) protein expression. Agreement between dichotomized ERCC1 and XPF scores was high at 79.4% (kappa = 0.587, P<.001). Neither biomarker predicted locoregional recurrence, DFS, or OS after adjustment for age and KPS, irrespective of stratification by stage, WHO type, or treatment.
Neither ERCC1 nor XPF, analyzed by quantitative immunohistochemistry using the FL297 and 3F2 antibodies, was prognostic or predictive in this cohort of NPC patients.
我们旨在评估 ERCC1 和 XPF 在接受根治性治疗的非转移性鼻咽癌（NPC）患者中的预后/预测价值。
使用 FL297 和 3F2 抗体通过免疫荧光结合自动定量分析（AQUA）分别评估 ERCC1 和 XPF 蛋白表达。将 ERCC1 和 XPF 蛋白表达水平与临床结局相关联。
患者特征如下：平均年龄 52 岁（范围，18-85 岁），67%为男性，72%的 Karnofsky 表现状态（KPS）≥90%，世界卫生组织（WHO）类型 1/2/3 分别为 12%/28%/60%，III/IV 期 65%。中位随访时间为 50 个月（范围，2.9 至 120 个月），5 年总生存率（OS）为 70.8%。中位数标准化核 AQUA 评分被用作 ERCC1（n=138）和 XPF（n=130）蛋白表达的截断值。二分类 ERCC1 和 XPF 评分之间的一致性很高，为 79.4%（kappa = 0.587，P<.001）。无论分期、WHO 类型或治疗如何分层，两种生物标志物均不能预测局部区域复发、DFS 或 OS，即使在调整年龄和 KPS 后也是如此。
在本批 NPC 患者中，使用 FL297 和 3F2 抗体通过定量免疫组化分析，既没有 ERCC1 也没有 XPF 具有预后或预测价值。
